Jennifer M. Johnson

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial”.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00658-6

N/A

4.8DataRank · unranked

234 citations

Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji +32 more

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1816

N/A

1.9DataRank · unranked

63 citations

Jennifer M. Johnson, Larry A. Harshyne, Alban J. Linnenbach, Sanket K. Shukla, Angela Alnemri +23 more

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist(2022)10.1093/oncolo/oyac080

N/A

1.7DataRank · unranked

49 citations

Christina S. Baik, Jessica R. Bauman, Jill Gilbert, Marcia S. Brose, Juneko E. Grilley‐Olson +13 more

Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1098

N/A

0.241DataRank · unranked

4 citations

Hani Samarah, Kathryn L. Nunes, Zhao Lin, Kelly Bridgham, Sruti Tekumalla +28 more

A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6026

N/A

0DataRank · unranked

0 citations

Yael Flamand, P. Savvides, Jennifer M. Johnson, Shuli Li, Arlene A. Forastiere +2 more

IL‐8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR‐146a mediated mechanism

Molecular Carcinogenesis(2023)10.1002/mc.23587

N/A

0DataRank · unranked

11 citations

Alyssa N. Calder, Joseph P Flemming, Yiyang Guo, S. Gilmore, Melissa A. Trofa +20 more

A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305

European Journal of Cancer(2023)10.1016/j.ejca.2023.113509

N/A

0DataRank · unranked

1 citations

Yael Flamand, P. Savvides, Jennifer M. Johnson, Ioannis Vathiotis, Marshall Levine +4 more

Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0037

N/A

0DataRank · unranked

10 citations

Kathryn L. Nunes, Pablo Llerena, Anastasia Nikitina, Anastasia Sobol, E. Reilly Scott +30 more

A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps6098

N/A

0DataRank · unranked

5 citations

Yael Flamand, Jennifer M. Johnson, Jeffrey J. Ishizuka, Fenghai Duan, Mei Tang +4 more

Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study

Cancers(2022)10.3390/cancers14051296

N/A

0DataRank · unranked

21 citations

Joshua Banks, Scott W. Keith, Andrew Song, Jennifer M. Johnson, Melissa Wilson +3 more

Monocarboxylate Transporter 4 in Cancer-Associated Fibroblasts Is a Driver of Aggressiveness in Aerodigestive Tract Cancers

Frontiers in Oncology(2022)10.3389/fonc.2022.906494

N/A

0DataRank · unranked

6 citations

Diana Whitaker‐Menezes, Mehri Mollaee, Zhao Lin, Madalina Tuluc, Nancy J. Philp +5 more

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

Frontiers in Oncology(2020)10.3389/fonc.2020.566315

N/A

0DataRank · unranked

55 citations

Jennifer M. Johnson, Madalina Tuluc, Stacey Gargano, Robert Stapp, Larry A. Harshyne +12 more